An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Transplantation of an individual's own tissue from one site to another site.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7)
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Inorganic or organic compounds that contain the basic structure RB(OH)2.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
The farthest or outermost projections of the body, such as the HAND and FOOT.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The action of a drug in promoting or enhancing the effectiveness of another drug.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
A mutant strain of Rattus norvegicus without a thymus and with depressed or absent T-cell function. This strain of rats may have a small amount of hair at times, but then lose it.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
An anti-inflammatory 9-fluoro-glucocorticoid.
An alkylating agent of value against both hematologic malignancies and solid tumors.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
A group of alkylating agents derived from mustard gas, with the sulfur replaced by nitrogen. They were formerly used as toxicants and vesicants, but now function as antineoplastic agents. These compounds are also powerful mutagens, teratogens, immunosuppressants, and carcinogens.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A 3:1 mixture of alfaxalone with alfadolone acetate that previously had been used as a general anesthetic. It is no longer actively marketed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1445)
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
Experimentally induced neoplasms of CONNECTIVE TISSUE in animals to provide a model for studying human SARCOMA.
Drugs used for their actions on histaminergic systems. Included are drugs that act at histamine receptors, affect the life cycle of histamine, or affect the state of histaminergic cells.

L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. (1/1170)

PET with L-[1-11C]-tyrosine (TYR) was investigated in patients undergoing hyperthermic isolated limb perfusion (HILP) with recombinant tumor necrosis factor alpha (rTNF-alpha) and melphalan for locally advanced soft-tissue sarcoma and skin cancer of the lower limb. METHODS: Seventeen patients (5 women, 12 men; age range 24-75 y; mean age 52 y) were studied. TYR PET studies were performed before HILP and 2 and 8 wk afterwards. The protein synthesis rates (PSRs) in nanomoles per milliliter per minute were calculated. After final PET studies, tumors were resected and pathologically examined. Patients with pathologically complete responses (pCR) showed no viable tumors after treatment. Those with pathologically partial responses (pPR) showed various amounts of viable tumors in the resected tumor specimens. RESULTS: Six patients (35%) showed a pCR and 11 patients (65%) showed a pPR. All tumors were depicted as hot spots on PET studies before HILP. The PSR in the pCR group at 2 and 8 wk after perfusion had decreased significantly (P < 0.05) in comparison to the PSR before HILP. A significant difference was found in PSR between the pCR and pPR groups at 2 and at 8 wk (P < 0.05). Median PSR in nonviable tumor tissue was 0.62 and ranged from 0.22 to 0.91. With a threshold PSR of 0.91, sensitivity and specificity of TYR PET were 82% and 100%, respectively. The predictive value of a PSR > 0.91 for having viable tumor after HILP was 100%, whereas the predictive value of a PSR < or = 0.91 for having nonviable tumor tissue after HILP was 75%. The 2 patients in the pPR groups with a PSR < 0.91 showed microscopic islets of tumor cells surrounded by extensive necrosis on pathological examination. CONCLUSION: Based on the calculated PSR after HILP, TYR PET gave a good indication of the pathological outcome. Inflammatory tissue after treatment did not interfere with viable tumor on the images, suggesting that it may be worthwhile to pursue TYR PET in other therapy evaluation settings.  (+info)

In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats. (2/1170)

Isolated perfusion of the extremities with high-dose tumour necrosis factor alpha (TNF-alpha) plus melphalan leads to dramatic tumour response in patients with irresectable soft tissue sarcoma or multiple melanoma in transit metastases. We developed in vivo isolated organ perfusion models to determine whether similar tumour responses in solid organ tumours can be obtained with this regimen. Here, we describe the technique of isolated kidney perfusion. We studied the feasibility of a perfusion with TNF-alpha and assessed its anti-tumour effects in tumour models differing in tumour vasculature. The maximal tolerated dose (MTD) proved to be only 1 microg TNF-alpha. Higher doses appeared to induce renal failure and a secondary cytokine release with fatal respiratory and septic shock-like symptoms. In vitro, the combination of TNF-alpha and melphalan did not result in a synergistic growth-inhibiting effect on CC 531 colon adenocarcinoma cells, whereas an additive effect was observed on osteosarcoma ROS-1 cells. In vivo isolated kidney perfusion, with TNF-alpha alone or in combination with melphalan, did not result in a significant anti-tumour response in either tumour model in a subrenal capsule assay. We conclude that, because of the susceptibility of the kidney to perfusion with TNF-alpha, the minimal threshold concentration of TNF-alpha to exert its anti-tumour effects was not reached. The applicability of TNF-alpha in isolated kidney perfusion for human tumours seems, therefore, questionable.  (+info)

Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. (3/1170)

Integrin-mediated adhesion influences cell survival and may prevent programmed cell death. Little is known about how drug-sensitive tumor cell lines survive initial exposures to cytotoxic drugs and eventually select for drug-resistant populations. Factors that allow for cell survival following acute cytotoxic drug exposure may differ from drug resistance mechanisms selected for by chronic drug exposure. We show here that drug-sensitive 8226 human myeloma cells, demonstrated to express both VLA-4 (alpha4beta1) and VLA-5 (alpha5beta1) integrin fibronectin (FN) receptors, are relatively resistant to the apoptotic effects of doxorubicin and melphalan when pre-adhered to FN and compared with cells grown in suspension. This cell adhesion mediated drug resistance, or CAM-DR, was not due to reduced drug accumulation or upregulation of anti-apoptotic Bcl-2 family members. As determined by flow cytometry, myeloma cell lines selected for drug resistance, with either doxorubicin or melphalan, overexpress VLA-4. Functional assays revealed a significant increase in alpha4-mediated cell adhesion in both drug-resistant variants compared with the drug-sensitive parent line. When removed from selection pressure, drug-resistant cell lines reverted to a drug sensitive and alpha4-low phenotype. Whether VLA-4-mediated FN adhesion offers a survival advantage over VLA-5-mediated adhesion remains to be determined. In conclusion, we have demonstrated that FN-mediated adhesion confers a survival advantage for myeloma cells acutely exposed to cytotoxic drugs by inhibiting drug-induced apoptosis. This finding may explain how some cells survive initial drug exposure and eventually express classical mechanisms of drug resistance such as MDR1 overexpression.  (+info)

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (4/1170)

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients.  (+info)

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). (5/1170)

Tumour-selective acidification is of potential interest for enhanced therapeutic gain of pH sensitive drugs. In this study, we investigated the feasibility of a tumour-selective reduction of the extracellular and intracellular pH and their effect on the tumour response of selected anti-cancer drugs. In an in vitro L1210 leukaemic cell model, we confirmed enhanced cytotoxicity of chlorambucil at low extracellular pH conditions. In contrast, the alkylating drugs melphalan and cisplatin, and bioreductive agents mitomycin C and its derivative EO9, required low intracellular pH conditions for enhanced activation. Furthermore, a strong and pH-independent synergism was observed between the pH-equilibrating drug nigericin and melphalan, of which the mechanism is unclear. In radiation-induced fibrosarcoma (RIF-1) tumour-bearing mice, the extracellular pH was reduced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) or its analogue benzylguanidine (BG) plus glucose. To simultaneously reduce the intracellular pH, MIBG plus glucose were combined with the ionophore nigericin or the Na+/H+ exchanger inhibitor amiloride and the Na+-dependent HCO3-/Cl- exchanger inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulphonic acid (DIDS). Biochemical studies confirmed an effective reduction of the extracellular pH to approximately 6.2, and anti-tumour responses to the interventions indicated a simultaneous reduction of the intracellular pH below 6.6 for at least 3 h. Combined reduction of extra- and intracellular tumour pH with melphalan increased the tumour regrowth time to 200% of the pretreatment volume from 5.7 +/- 0.6 days for melphalan alone to 8.1 +/- 0.7 days with pH manipulation (P < 0.05). Mitomycin C related tumour growth delay was enhanced by the combined interventions from 3.8 +/- 0.5 to 5.2 +/- 0.5 days (P < 0.05), but only in tumours of relatively large sizes. The interventions were non-toxic alone or in combination with the anti-cancer drugs and did not affect melphalan biodistribution. In conclusion, we have developed non-toxic interventions for sustained and selective reduction of extra- and intracellular tumour pH which potentiated the tumour responses to selected anti-cancer drugs.  (+info)

Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. (6/1170)

Transplantation after high-dose chemotherapy prolongs survival in patients with multiple myeloma compared with standard therapy. It is unclear whether the optimal timing of transplantation is immediately after induction chemotherapy or whether stem cells may be cryopreserved for transplantation at subsequent progression or relapse. In this study, stem cells were collected within 6 months of diagnosis, followed by transplantation only at progression of myeloma. One hundred and eighteen patients with multiple myeloma had stem cells collected and cryopreserved. Eleven had transplants early in the disease after they demonstrated failure to respond to primary therapy. The remaining 107 were eligible for transplants when there was evidence of progressive disease. Of the 118 patients, 67 had transplants, nine died of progressive disease before transplantation, and 42 remain alive in plateau phase. The median survival of the group is 58.5 months; 67 are alive. Serum beta2-microglobulin, bone marrow labeling index (S phase), and hemoglobin level predicted overall survival (P < 0.006, P < 0.001, and P < 0.01, respectively). We conclude that early cryopreservation of blood stem cells followed by transplantation at progression is a feasible approach to therapy in patients with myeloma. The underlying biology of the disease has a greater impact on survival than the timing of transplantation. A prospective randomized trial is required to answer definitively the question of the optimal timing of blood cell transplantation.  (+info)

Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. (7/1170)

A patient with a stage IV mantle cell lymphoma (according to the REAL classification) was treated with high-dose chemotherapy and autologous bone marrow transplantation. One year later while on alpha-interferon immunotherapy she suffered from progressive loss of short-term memory and reported difficulties in recognizing objects. Magnetic resonance imaging (MRI) showed a vast ring-enhancing lesion of the left postcentral parietal area. Serial stereotactic biopsies disclosed progressive multifocal leukoencephalopathy without JC-virus in the cerebrospinal fluid. Therapy with subcutaneous interleukin-2 (IL-2) every other day and intrathecal cytarabine once a week was started. After 4 weeks the patient refused further treatment. Nevertheless her condition improved over the next 8 months and MRI scans showed a marked improvement in the lesions.  (+info)

Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study. (8/1170)

The idiotype (Id) determinant on the multiple myeloma (MM) protein can be regarded as a tumor-specific marker. Immunotherapy directed at the MM Id may stem the progression of this disease. We report here on the first 12 MM patients treated at our institution with high-dose therapy and peripheral blood stem cell transplantation (PBSCT) followed by Id immunizations. MM patients received PBSCT to eradicate the majority of the disease. PBSCT produced a complete response in 2 patients, a partial response in 9 patients and stable disease in 1 patient. Three to 7 months after high-dose therapy, patients received a series of monthly immunizations that consisted of two intravenous infusions of Id-pulsed autologous dendritic cells (DC) followed by five subcutaneous boosts of Id/keyhole limpet hemocyanin (KLH) administered with adjuvant. Between 1 and 11 x 10(6) DC were obtained by leukapheresis in all patients even after PBSCT. The administration of Id-pulsed DC and Id/KLH vaccines were well tolerated with patients experiencing only minor and transient side effects. Two of 12 patients developed an Id-specific, cellular proliferative immune response and one of three patients studied developed a transient but Id-specific cytotoxic T-cell (CTL) response. Eleven of the 12 patients generated strong KLH-specific cellular proliferative immune responses showing the patients' immunocompetence at the time of vaccination. The two patients who developed a cellular Id-specific immune response remain in complete remission. Of the 12 treated patients, 9 are currently alive after autologous transplantation with a minimum follow-up of 16 months, 2 patients died because of recurrent MM and 1 patient succumbed to acute leukemia. These studies show that patients make strong anti-KLH responses despite recent high-dose therapy and that DC-based Id vaccination is feasible after PBSCT and can induce Id-specific T-cell responses. Further vaccine development is necessary to increase the proportion of patients that make Id-specific immune responses. The clinical benefits of Id vaccination in MM remain to be determined.  (+info)

TY - JOUR. T1 - Prevention of the development of melphalan resistance in vitro by selenite. AU - Caffrey, Paula B.. AU - Zhu, Ming. AU - Frenkel, Gerald D.. PY - 1998/1/1. Y1 - 1998/1/1. N2 - Exposure of A2780 human ovarian tumor cells to a low concentration of melphalan in vitro for 7 d results in the development of melphalan resistance, which is dependent on elevated cellular levels of glutathione and glutathione S-transferase. The inclusion of selenite (at concentrations as low as 0.2 μM) during the exposure to melphalan completely prevented the development of resistance. Selenite did not prevent the melphalan-induced increase in glutathione, but it did prevent the increase in the activity of glutathione S-transferase. It also prevented the increase in the expression of the glutathione S-transferase gene, suggesting that this may be the mechanism by which it prevents the development of melphalan resistance. The results of this in vitro study suggest that selenite may prove to be useful in ...
In this study the investigators are comparing this standard regimen to the newly established regimen of melphalan and bortezomib.. Conditioning Regimens:. Treatment arm A Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.. Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.. Dosing will be based on body surface area calculated using actual body weight. Stem cell infusion:. Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.. Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least).. Treatment arm B. Bortezomib:. Bortezomib is administered by rapid I.V. push (over ...
Define L-phenylalanine mustard. L-phenylalanine mustard synonyms, L-phenylalanine mustard pronunciation, L-phenylalanine mustard translation, English dictionary definition of L-phenylalanine mustard. n a drug, C13H18Cl2N2O2, used to treat myeloid leukaemia Noun 1. melphalan - antineoplastic drug used to treat multiple myeloma and some other malignancies...
PRIMARY OBJECTIVES:. I. Compare the complete response (CR) and near CR rate in patients undergoing autologous stem cell transplant (ASCT) using melphalan 280 mg/m^2 or melphalan 200 mg/m^2.. SECONDARY OBJECTIVES:. I. Compare toxicities between patients receiving amifostine and melphalan 280 mg/m^2 or melphalan 200 mg/m^2.. OUTLINE: Patients are randomized to 1 of 2 treatment arms.. INDUCTION THERAPY:. ARM I (HIGH DOSE MELPHALAN AND AMIFOSTINE): Patients receive amifostine intravenously (IV) over 3-5 minutes on days -3 and -2 followed by high-dose melphalan IV over 15-30 minutes on day 2.. ARM II (LOW DOSE MELPHALAN AND AMIFOSTINE): Patients receive amifostine as in arm I and melphalan as in arm I at a lower dose.. AUTOLOGOUS OR SYNGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT): At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.. Patients undergo restaging of the disease between days 80-90. Patients with progressive disease are ...
In a phase III trial reported in The New England Journal of Medicine, Palumbo et al found that consolidation therapy with high-dose melphalan plus autologous stem cell transplantation improved progression-free survival and overall survival compared with melphalan/prednisone/lenalidomide (Revlimid) consolidation and that lenalidomide maintenance vs no maintenance improved progression-free survival in patients ≤ 65 years newly diagnosed with multiple myeloma.. Study Details. In this open-label trial, 273 patients aged ≤ 65 years with newly diagnosed multiple myeloma from 62 centers in Israel and Italy were randomly assigned between November 2007 and July 2009 to receive high-dose melphalan (200 mg/m2) followed by autologous stem cell transplantation (n = 141) or melphalan/prednisone/lenalidomide consolidation (n = 132) after induction therapy with lenalidomide and dexamethasone. Of these, a total of 251 were further randomly assigned to lenalidomide maintenance after high-dose melphalan ...
BACKGROUND AND OBJECTIVES: Since optimal collection of peripheral blood progenitor cells (PBPC) remains crucial for high-dose therapy in patients with multiple myeloma (MM) in relapse phase or refractory to chemotherapy, we evaluated several variables that may influence mobilization. DESIGN AND METHODS: Eighty-nine patients who underwent a standard mobilization procedure with cyclophosphamide (3 g/m2) and growth factors entered the study. A composite collection totalling at least 2x106 CD34+/kg was defined as a sufficient yield: 59 patients achieved an adequate collection. A reliable factor to predict adequate yields was prior therapy: an adequate collection was obtained in 92% of patients treated with conventional non-alkylating therapy (VAD-based regimens), in 56% treated with oral melphalan and in 23% who had received intravenous melphalan. RESULTS: The three groups were similar for most clinical features. After adjustment for several potential confounders, the probability of an adequate PBPC ...
Taylor, P. R. A., Jackson, G. H., Lennard, A. L., Lucraft, H. H., Proctor, S. J., Abela, M., Angus, B., Branson, A. N., Browning, N. M., Cartner, R., Carey, P. J., Galloway, M. J., Chandler, J. C., Condie, P., Dewar, M., Evans, R. G. B., Finney, R. D., Goff, D., Hamilton, P. J ...
TY - JOUR. T1 - Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation. T2 - A prospective study of 22 patients with hematologic malignancies. AU - Rodriguez, Roberto. AU - Parker, P.. AU - Nademanee, A.. AU - Smith, D.. AU - ODonnell, M. R.. AU - Stein, A.. AU - Snyder, D. S.. AU - Fung, H. C.. AU - Krishnan, A. Y.. AU - Popplewell, L.. AU - Cohen, S.. AU - Somlo, G.. AU - Angelopoulou, M.. AU - Al-Kadhimi, Z.. AU - Falk, P. M.. AU - Spielberger, R.. AU - Kogut, N.. AU - Sahebi, F.. AU - Senitzer, D.. AU - Slovak, M.. AU - Schriber, J.. AU - Forman, S. J.. PY - 2004/6/1. Y1 - 2004/6/1. N2 - In an attempt to decrease toxicity in high-risk patients undergoing unrelated donor hematopoietic stem cell transplantation (URD HSCT), we tested a combination of cyclosporine (CSP) and mycophenolate mofetil (MMF) as graft-versus-host disease (GVHD) prophylaxis with the reduced-intensity conditioning regimen fludarabine/melphalan ...
Isolated pelvic perfusion (IPP) can be used to treat unresectable melanoma metastases of the pelvis. IPP can be performed either by surgical or percutaneous approaches, using different balloon catheters. The aim of this study was to examine whether the surgical and percutaneous approaches were comparable with respect to tumor drug exposure in the pelvis. A pharmacokinetic study was performed in 5 melanoma patients treated with surgical IPP and five with percutaneous IPP. Both groups received melphalan at the dose of 30 mg/m2. Melphalan pharmacokinetic analyses were performed and the main parameter used to evaluate pelvic tumor drug-exposure was the ratio of areas under the melphalan plasma concentration curves in the pelvis and the systemic compartment, during the perfusion time (AUC0 to 20). Non-parametric Mann-Whitney tests were employed for statistical comparisons. The median and interquartile range (IQR) values of the ratios between melphalan AUC0 to 20 in pelvic and systemic compartments were 7.9
Another amino acid-like drug is the antineoplastic agent melphalan. Tumor cells spend less time in resting phases than normal cells so at any given time, they are more likely to be metabolically active than most normal host cells. The rationale behind incorporating an alkylating function in a molecule resembling a primary cellular metabolite was to get a greater safety margin by fooling tumor cells into taking up the toxin preferentially. ...
Search Indian Alphalan Melphalan Manufacturers and Suppliers Details - Contact to Alphalan Melphalan Exporters in India, Alphalan Melphalan Wholesalers, Alphalan Melphalan Distributors and Traders from India.
The Role of High Dose Chemotherapy With Autologous Stem Cell Rescue in Multiple Myeloma in the Era of Conventional Cytotoxic Chemotherapy. Before the introduction of proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs), high dose melphalan with ASCT following induction therapy was considered the standard approach for transplant-eligible patients with newly diagnosed MM. The first randomized controlled trial from the Intergroupe Francais du Myelome (IFM90), published in 1996, randomized newly diagnosed MM patients to an older chemotherapy regimen (vincristine/carmustine, cyclophosphamide, prednisone alternating with carmustine, vincristine, adriamycin, prednisone; VMCP/BVAP) for 12 cycles versus 4 to 6 cycles of VMCP/BVAP followed by high dose therapy with autologous bone marrow transplant.1 Those patients randomized to the transplant arm compared with the high dose chemotherapy arm had a superior 5-year event-free survival (EFS) (28% versus 10%, respectively, P = .01) and OS (52% ...
Melphalan is used as a "palliative" treatment to relieve symptoms of multiple myeloma (a type of blood cancer) or a certain type of ovarian cancer. Melphalan injection is used as a "conditioning" treatment for multiple myeloma before you receive a stem cell transplant. Melphalan may also be used for...
All information about the latest scientific publications of the Clínica Universidad de Navarra. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
The results show that the activity of the dipeptide mustards is highly dependent on intracellular hydrolysis, which result in rapid intrACEllular release of the alkylating unit in cells with high enzymatic activity. Recently, we presented a series of melphalan containing di- and tripeptides with high cytotoxic activity and J1 (l-melphalanyl-p-l-fluorophenylalanine ethyl ester) was identified as one of the most interesting compounds. It was speculated that the increased activity compared to melphalan itself, demonstrated both in vitro and in vivo, resided in increased transport over the tumour cell membrane and/or hydrolytic cleavage and liberation of melphalan inside the cells. Indeed, overexpression of hydrolytic enzymes like peptidases, esterases and proteases has been described in several types of human malignancies, thus providing a target for selective chemotherapy. In this work, the details of the increased activity was further investigated and potential tumour selectivity is discussed. The
PEPAXTO is contraindicated in patients with a history of serious allergic reaction to melphalan flufenamide or melphalan.. PEPAXTO may cause thrombocytopenia, which may lead to hemorrhage. Monitor platelets at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first 2 months of treatment with PEPAXTO. Do not administer PEPAXTO if the platelet count is less than 50 x 109/L. Withhold PEPAXTO until platelet count is 50 x 109/L or greater and resume at same or reduced dose based on duration of interruption. Adjust dose and/or dose schedule based on signs and symptoms of bleeding.. PEPAXTO may cause neutropenia, which may lead to infection. Monitor neutrophil counts at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first 2 months of treatment with PEPAXTO. Do not administer PEPAXTO if absolute neutrophil count is less than 1 x 109/L. Withhold PEPAXTO until absolute neutrophil count is 1 x 109/L or greater and resume ...
Solid tumors provide an environment conducive to bioreduction due to hypoxia and overexpression of bioreductive enzymes. Therefore, TDDS were designed with various substituents to modulate bioreductive activation. TDDS contain a quinone-based carrier coupled to the model drug, melphalan methyl ester (MME). Controlled bioreductive activation of TDDS can lead to specific drug release only at the tumor sites and hence reduce toxicity during systemic distribution. The rate and extent of bioreductive activation of TDDS was determined in presence of DT-diaphorase, xanthine oxidase, human breast tumor cells (MCF-7) and colon tumor cells (Caco-2). Stability of TDDS under aqueous buffer conditions and in the presence of glutathione was also evaluated. Anticancer activity of TDDS was determined based on alkylating activity, cytotoxicity and apoptotic induction in both the tumor cell lines. Results show that all TDDS especially CH3-TDDS improved stability of melphalan under pH 7.4. H-TDDS possessed ...
The use of stem cell transplantion (SCT) therapy has also been explored in patients WM. Desikan et al177 reported their initial experience of high-dose chemotherapy and autologous stem cell transplant, which has more recently been updated by Munshi et al.178 Their studies involved eight previously treated WM patients between the ages of 45 and 69 years, who received either melphalan at 200mg/m2 (n = 7) or melphalan at 140mg/m2 along with total body irradiation. Stem cells were successfully collected in all eight patients, although a second collection procedure was required for two patients who had extensive previous nucleoside analogue exposure. There were no transplant related mortalities and toxicities were manageable. All eight patients responded, with 7 of 8 patients achieving a major response, and one patient achieving a complete response with durations of response raging from 5+ to 77+ months. Dreger et al179 investigated the use of the DEXA-BEAM (dexamethasone, BCNU, etoposide, ...
Fludarabine, Melphalan, Total-Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders…
The current studies demonstrate that MOPC-315 tumor cells secrete large amounts of interleukin-10 (IL-10), which contributes to the inhibitory activity of MOPC-315 culture supernatants for the in vitro generation of antitumor cytotoxicity by MOPC-315-immune spleen cells. Moreover, addition of neut …
Alkeran tablets and injection contain the active ingredient melphalan, which is a type of chemotherapy medicine to treat cancer called an alkylating agent.
Generic name Melphalan hydrochloride Pronunciation MEL-fa-lan HIGH-droe-KLOR-ide Brand name(s), other common name(s) EvomelaTM Drug type Alkylating agent How the drug is given
Citation: Shelby, M.D., Gulati, D.K., Tice, R.R., and Wojciechowski, J.P. Results of tests for micronuclei and chromosomal aberrations in mouse bone marrow cells with the human carcinogens 4-aminobiphenyl, treosulphan, and melphalan. Environ. Molec. Mutagen. Vol. 13 (1989) 339- ...
ALKERAN (Melphalan) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
Buy Melphalan Hydrochloride online at LGC Standards. High quality reference standards for the most reliable pharmaceutical testing.
We have isolated cis-diamminedichloroplatinum(II) (CDDP)-resistant variants, C/CDP-1 and C/CDP-2, from a Chinese hamster ovary (CHO) cell line after a stepwise exposure to increasing concentrations of CDDP, and a CDDP-sensitive revertant, R-1, from C/CDP-2 after continuous incubation for 5 months in the absence of CDDP. C/CDP-1 and C/CDP-2 showed 7- and 10-fold higher resistance to CDDP, respectively, compared to CHO cells. C/CDP-2 was cross-resistant to carboplatin, l-phenylalanine mustard (melphalan), and CdSO4, but not to other anticancer agents. Alkaline elution of DNA showed an increased amount of DNA interstrand cross-linking formation in CHO cells, but not in C/CDP-2 cells, when CHO and C/CDP-2 cells were cultured with CDDP. By contrast, alkaline elution of DNA showed increased formation of DNA cross-links when nuclei of C/CDP-2 cells were treated with CDDP. The activity of glutathione S-transferase (GST) of C/CDP-1 and C/CDP-2 was 4- and 6-fold higher than that of CHO cells, ...
Introduction. High dose melphalan 200mg/m2 (MEL200) followed by autologous stem cell transplantation (ASCT) is the standard of care for fit patients with Multiple Myeloma (MM). Bendamustine has been shown to induce responses in MM resistant to other alkylating agents. Our prior Phase I trial, adding bendamustine to MEL200, demonstrated no additional toxicity above that expected with MEL200 alone (Mark et. al. BBMT 2013). A phase 2 trial of bendamustine/MEL200 conditioning was conducted to evaluate treatment efficacy. Objective and Methods. This single arm, open-label, phase II study was designed to establish the efficacy of Bendamustine (225 mg/m2) in combination with MEL200 in patients undergoing first ASCT for MM. Patients 18 to 75 years with confirmed MM, prior induction therapy, adequate mobilization (at least 2x106 of CD34+ hematopoietic stem cells), Karnofsky performance status ,70% and life expectancy ,12 weeks were eligible for screening. Major exclusion criteria included ...
The combination of oral melphalan and dexamethasone is considered standard therapy for patients with light-chain amyloidosis ineligible for autologous stem cell transplantation. However, previous trials reported different rates of response and survival, mainly because of the different proportions of …
TY - JOUR. T1 - Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. AU - Libutti, Steven K.. AU - Bartlett, David L.. AU - Fraker, Douglas L.. AU - Alexander, H. Richard. PY - 2000. Y1 - 2000. N2 - Background: For a variety of histologies, the liver represents the only or the dominant site of metastatic disease. Regional treatment of the liver has the theoretic advantage of maximizing drug delivery while minimizing systemic toxicity. This article describes the technique of isolated hepatic perfusion using tumor necrosis factor and melphalan under conditions of moderate hyperthermia for the treatment of unresectable liver tumors. Study Design: Fifty patients with biopsy-proved unresectable primary or metastatic cancer to the liver were treated. Isolated hepatic perfusion was performed for 60 minutes under conditions of moderate hyperthermia during a laparotomy with inflow through the ...
Oligopeptides can be used to carry cytotoxic agents in cancer chemotherapy, using tumour-associated proteins as the molecular target for selectivity. During the seventies and eighties Peptichemio, a cocktail of six alkylating oligopeptides carrying m-L-sarcolysin, was investigated in a wide variety of human malignancies. Positive clinical results were suggested to result from rapid and effective DNA-crosslinking following uptake in neoplastic cells, but also from antimetabolic properties of the drug. Although m-L-sarcolysin never reached widespread clinical use, the well established para-isomer melphalan still, after nearly fifty years, has a place in cancer chemotherapy.. The present study was undertaken to synthesise the melphalan containing analogue of the tripeptide P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester, the main contributor to Peptichemios activity) and similar compounds, preferably dipeptides. The new compounds compared favourably with melphalan, m-L-sarcolysin ...
A case series of three patients by Francis et al. has investigated the response and toxicity of intravitreal melphalan treatment for non-vitreous retinoblastoma that was refractory to multiple-course ophthalmic artery chemosurgery (OAC). Patients Three eyes received a median of 7 weekly intravitreal melphalan injections (30μg/0.07cc). The toxicity of treatment was measured by electroretinogram (ERG) and the response to treatment was clinically evaluated. All eyes remained tumor-free at a median of 14 months follow-up. One eye was enucleated due to a vitreous hemorrhage that obscured fundus details. One eye had extinguished ERG recordings prior to injections and two eyes had a decrease in ERG responses over the intravitreal treatment course. The eye with subretinal seeding demonstrated marked retinopathy by ophthalmoscopy and fluorescein angiography and one eye was enucleated due to the development of a vitreous hemorrhage. This small case series highlights that non-vitreous disease that is ...
All information about the latest scientific publications of the Clínica Universidad de Navarra. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma
A number of strategies have been proposed to improve the outcome of ASCT. The three main strategies are to incorporate novel agents into the induction r
POEMS syndrome is a rare plasma cell dyscrasia. This study compared the responses to and survival of 347 POEMS syndrome patients given three first-line treatment regimens: autologous stem cell transplantation (ASCT, N = 165) and melphalan + dexamethasone (MDex, N = 79), or lenalidomide + dexamethasone (LDex, N = 103). After a median 45-month follow-up, overall hematologic complete remission (CRH) was 46.4%, vascular endothelial growth factor complete remission (CRV) was 55.1%, and neurological remission (RN) was 93.8%. CRH was better with ASCT (49.7%) than with MDex (37.7%, p = 0.001). CRV was better with ASCT (66.2%) than with MDex (38.5%, p = 0.001) or LDex (47.7%, p = 0.008). Differences in RN achieved by three regimens (91.5% vs. 100% vs. 93.8%, p = 0.234) were not significant. Overall 3-year progression-free survival (PFS) was 80.5% and overall 3-year overall survival (OS) was 90.8%. PFS was 87.6% with ASCT and 64.9% with LDex (p = 0.003). OS in the three regimens did not differ (p = 0.079). In
Background and Objective. High-dose sequential chemotherapy (HDS) has been given to patients with Hodgkins disease (HD) before autologous hematopoietic stem cell transplantation (HSCT), but its effectiveness has not been evaluated in comparison with less-aggressive regimens. In this study we compared HDS with a less-aggressive regimen as preparation to autologous HSCT in patients with HD. Design and Methods. Retrospective non-randomized comparison between patients receiving HDS (group 1, n=52) or a less-aggressive regimen (group 2, n=60). HDS consisted of the sequential administration of cyclophosphamide (7 g/m 2) and G-CSF (300 μg/day) with stem cell collection, methotrexate (8 g/m2) plus vincristine (1.4 mg/m2), and etoposide (2 g/m2). Group 2 patients received of 2 cycles of DHAP, followed by cyclophosphamide (1.5 g/m2) plus G-CSF and stem cell collection. Results. Group 1 patients were more likely to have stage IV (40% vs. 13%, p=0.001) and bulky disease (62% vs. 39%, p=0.02) at diagnosis. ...
Consolidation with melphalan and autologous stem-cell transplantation (ASCT) remains the preferred option in transplant-eligible multiple myeloma.
In multiple myeloma, combination chemotherapy with melphalan plus prednisone has been usedsince the 1960s and is regarded as the standard of care in ver
Melphalan (US brand name Alkeran) is a chemotherapy drug commonly used to treat multiple myeloma. See common side effects and how its used.
Fingerprint Dive into the research topics of Combination therapy with Melphalan, Prednisone, and Thalidomide (MPT) for multiple myeloma. Together they form a unique fingerprint. ...
112 Patienten wurden im Rahmen von 2 prospektiven multizentrischen Phase-II Studien mit einer isolierten Extremitätenperfusion mit Tumornekrosefaktor (TNF) und Melphalan behandelt. Hiervon waren 49 Patienten an einem lokoregionär metastasierten Melanom und 63 Patienten an einem lokal fortgeschrittenen Weichgewebssarkom erkrankt. Bei Patienten mit regionären Metastasen eines Melanoms fand sich in 46 % eine komplette und in 20 % eine partielle Remission. Die mittlere lokoregionäre progressionsfreie Zeit war 32,3 Monate (Median 15,6 Monate). Sie war signifikant länger bei Patienten mit einer kompletten Remission (46,0 Monate, Median 30,2 Monate) im Vergleich zu Patienten mit einer partiellen Remission (15,2 Monate, Median 16,1 Monate) oder Patienten mit unverändertem Befund (7,2 Monate, Median 6,0 Monate). Die Gesamt-Überlebenszeit der Patienten mit Melanom betrug im Mittel 42,6 Monate (Median 24,4 Monate) und die 5-Jahres-Überlebensrate 42 %. Die klinische Ansprechrate der Patienten mit ...
112 Patienten wurden im Rahmen von 2 prospektiven multizentrischen Phase-II Studien mit einer isolierten Extremitätenperfusion mit Tumornekrosefaktor (TNF) und Melphalan behandelt. Hiervon waren 49 Patienten an einem lokoregionär metastasierten Melanom und 63 Patienten an einem lokal fortgeschrittenen Weichgewebssarkom erkrankt. Bei Patienten mit regionären Metastasen eines Melanoms fand sich in 46 % eine komplette und in 20 % eine partielle Remission. Die mittlere lokoregionäre progressionsfreie Zeit war 32,3 Monate (Median 15,6 Monate). Sie war signifikant länger bei Patienten mit einer kompletten Remission (46,0 Monate, Median 30,2 Monate) im Vergleich zu Patienten mit einer partiellen Remission (15,2 Monate, Median 16,1 Monate) oder Patienten mit unverändertem Befund (7,2 Monate, Median 6,0 Monate). Die Gesamt-Überlebenszeit der Patienten mit Melanom betrug im Mittel 42,6 Monate (Median 24,4 Monate) und die 5-Jahres-Überlebensrate 42 %. Die klinische Ansprechrate der Patienten mit ...
Health,...Launch represents first available generic equivalent of Alkeran(R) ... ...LAKE FOREST Ill. and NEWTOWN Pa. June 9 /- Bioniche P... ...,Bioniche,Pharma,and,Synerx,Pharma,Launch,Melphalan,Hydrochloride,for,Injection,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Bone marrow consists of several kinds of cells. These cells manufacture many chemicals known as proteins. One kind of bone marrow cell (plasma cell) makes a protein called amyloid that is produced in different forms. One form is lighter in weight than others. Abnormal plasma cells may produce too much light amyloid, which results in a disease called AL amyloidosis. This protein is then deposited in different organs, causing progressive disability and death. Without treatment, patients usually die within about a year. If amyloid deposits affect the heart, death occurs more rapidly (in about 5 months). Treatment with a drug called melphalan destroys abnormal plasma cells and, when given by mouth, can lengthen survival. A promising new approach to treatment involves giving high-dose melphalan intravenously. However, this approach also kills normal bone marrow cells, which must then be replaced. This is done by collecting a special type of cell (known as stem cells) from the patients bone marrow or ...
Background: Multiple myeloma (MM) is a B-cell malignancy, where malignant plasma cells clonally expand in the bone marrow of older people, causing significant morbidity and mortality. Typical clinical symptoms include increased serum calcium levels, renal insufficiency, anemia, and bone lesions. With standard therapies, MM remains incurable; therefore, the development of new drugs or immune cell-based therapies is desirable. To advance the goal of finding a more effective treatment for MM, we aimed to develop a reliable preclinical MM mouse model applying sensitive and reproducible methods for monitoring of tumor growth and metastasis in response to therapy. Material and Methods: A mouse model was created by intravenously injecting bone marrow-homing mouse myeloma cells (MOPC-315.BM) that expressed luciferase into BALB/c wild type mice. The luciferase in the myeloma cells allowed in vivo tracking before and after melphalan treatment with bioluminescence imaging (BLI). Homing of MOPC-315.BM ...
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. ...
Abstract. VTD as well as MPT chemotherapies have been known to be most active regimens in patients (pts) with MM. The objective of this study is to evaluate re
After the very high dose of chemotherapy (Melphalan) on Valentines Day and the Stem Cell Transplant on Day 0 (the birth of Munira, Version 2.0), the rest of the time in the hospital has been waiting for the stem cells to engraft, and for me to manage the devastating effects of the chemo. And what…
Cornelis J. H. van de Velde is the author of this article in the Journal of Visualized Experiments: Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Arian R. van Erkel is the author of this article in the Journal of Visualized Experiments: Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
This trial is assessing the efficacy and safety of bortezomib when used along with dexamethasone, melphalan, cisplatin, thalidomide and lenalidomide in lower
Melphalan is a DNA alkylating agent; induces cytotoxicity through the formation of stable interstrand and intrastrand crosslinks within DNA which inhibits growth of PC-3 cells (IC50 values are 0.074 and 0.77 μM for sequential dosing and single dosing respectively). Learn More ...
This talk will focus on the current literature associated with regional limb perfusion and provide technical details of performing regional limb perfusions in the field. In addition, cases and indications of use will be discussed along with common pitfalls or failures seen with the procedure that may lead to a failure in response to treatment. There will be a discussion of the prognosis seen with its use verses without. ...
While recent popular uprisings have had a tendency to be varied, uncertain or unexpected, they can be seen as standard bearers of the emergence (...)
October 2007). "Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous ... "Alkeran- melphalan tablet, film coated". DailyMed. 18 November 2019. Retrieved 23 April 2022. "Evomela- melphalan injection, ... Melphalan was approved for medical use in the United States in 1964. It is on the World Health Organization's List of Essential ... Melphalan belongs to the class of nitrogen mustard alkylating agents. It works by interfering with the creation of DNA and RNA ...
... is a peptidase enhanced cytotoxic (PEnC) that exerts a targeted delivery of melphalan in cells with high ... Compared to melphalan, melphalan flufenamide exhibits significantly higher in vitro and in vivo activity in several models of ... This suggests that melphalan flufenamide is rapidly and widely distributed to extravasal tissues, in which melphalan is formed ... Melphalan flufenamide rapidly disappeared from plasma after infusion, while melphalan typically peaked a few minutes after the ...
Examples include melphalan and chlorambucil. The following three groups are almost always considered "classical". Nitrogen ... Uramustine or uracil mustard Melphalan Chlorambucil Ifosfamide Bendamustine Nitrosoureas Carmustine Lomustine Streptozocin ...
Defty, CL; Marsden, JR (2012). "Melphalan in regional chemotherapy for locally recurrent metastatic melanoma". Current Topics ...
Evomela (melphalan) is an alkalyating drug for multiple myeloma. As of 2019, a number of drugs are investigated in clinical ...
Most chemotherapy is delivered intravenously, although a number of agents can be administered orally (e.g., melphalan, busulfan ... Dexamethasone along with either bortezomib or melphalan is commonly used as a treatment for AL amyloidosis. Recently, ... Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan. Nitrosoureas ... melphalan) including CDDP could be reversed at least partially by the addition of heat. Chemotherapy is used in veterinary ...
Other nitrogen mustards developed include cyclophosphamide, chlorambucil, uramustine, melphalan, and bendamustine. Bendamustine ...
Treatment with bortezomib, melphalan, and prednisone had an estimated overall survival of 83% at 30 months, lenalidomide plus ... For these people, the standard of care has been chemotherapy with melphalan and prednisone. Recent studies among this ... such as melphalan, cyclophosphamide, thalidomide, or dexamethasone, alone or in combination), and a second ASCT. Later in the ... "Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma". New England Journal of Medicine. 359 (9): ...
Meiotic inter-strand DNA damages caused by melphalan can escape paternal repair and cause chromosomal aberrations in the zygote ... Melphalan is a bifunctional alkylating agent frequently used in chemotherapy. ...
The drugs for which it receives royalties include Kyprolis, Promacta, Melphalan and Baxdela. As of 2015, Ligand Pharmaceuticals ...
"VELCADE as Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone". Millennium Corporate ...
The EWOG-MDS study also involves cyclophosphamide and melphalan in its conditioning regimen. Post transplant management: ...
Improvement has also been noted with autologous stem cell transplantation, and chemotherapy with melphalan. Chahin N, Selcen D ...
"Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma", News-Medical.Net, 20 July 2015, retrieved 6 ... NASDAQ: DCTH) a specialty pharmaceutical and medical device company manufactures melphalan. By 2011 the oral medications for ... melphalan (trade name Alkeran), busulfan, capecitabine). Delcath Systems, Inc. ( ...
EMA has also approved it to treat MM in combination with prednisone and/or melphalan. Orphan indications by the FDA include ...
High-dose melphalan in conjunction with autologous stem cell transplantation has been used in some patients. A regimen of ...
The four-drug combination helped in the increased overall remission rate, but was more toxigenic than melphalan. The four-drug ... regimen is more effective than melphalan in the management of advanced ovarian adenocarcinoma. ST8 suppression of ...
In 2009, GSK granted Aspen rights to produce melphalan and received a 16% shareholding in return. In 2013, Aspen expanded its ... In 2017 in France, three people died after being given cyclophosphamide, an alternative drug to Aspen's melphalan which had ... melphalan, mercaptopurine, tioguanine and busulfan. In July 2020, the European Commission found that throughout Aspen's ...
... and melphalan. There needs to be more research done to determine appropriate dosing and combinations of these drugs to advance ...
... is used as a first-line treatment in multiple myeloma in combination with dexamethasone or with melphalan and ... It was also evaluated whether thalidomide can be combined with melphalan and prednisone for patients with multiple myeloma. ... including doxorubicin and melphalan) concurrently. Thalidomide may interfere with various contraceptives, and hence it is ...
... melphalan, chlorambucil and chlormethine. Drugs with medium risk include doxorubicin and platinum analogs such as cisplatin and ...
"Ice-cream used as cryotherapy during high-dose melphalan conditioning reduces oral mucositis after autologous hematopoietic ...
... with neutrophil and platelet recovery in patients receiving autologous marrow transplantation after high-dose melphalan ...
People were randomized to receive either nine cycles of oral melphalan (M) plus prednisone (P) or MP plus bortezomib. People ... It was seen that bortezomib plus lenalidomide plus dexamethasone as well as bortezomib plus melphalan and prednisone may result ...
Hematological response rates to the dexamethasone/melphalan regimens have been reported to be in the 80% range with ... a corticosteroid such as dexamethasone plus an alkylating agents such as melphalan. Dosage regimens are selected on the basis ... neurological response rates approaching 100%. Patients successfully treated with the high-dose dexamethasone/melphalan regimen ...
... melphalan, chlorambucil and chlormethine. Drugs with medium risk include doxorubicin and platinum analogs such as cisplatin and ...
... polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan". ...
... polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan". ...
It has been reported that clearance of lesions can be done with melphalan and cyclophosphamide alone or in combination with ...
Use under this protocol, usually with fludarabine and melphalan, was developed by oncologists at the University of Texas MD ...
Melphalan: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Melphalan is used to treat multiple myeloma (a type of cancer of the bone marrow). Melphalan is also used to treat a certain ... Before taking melphalan,. *tell your doctor and pharmacist if you are allergic to melphalan, any other medications, or any of ... Melphalan may increase the risk that you will develop other cancers. Talk with your doctor about the risks of taking melphalan. ...
Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition ... Cisplatin/Doxorubicin/Melphalan/Teniposide regimen. Doxorubicin/Melphalan/Teniposide regimen (MAV). In Blood ... Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients ... A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and ...
Melphalan Hydrochloride (UNII: 1VXP4V453T) (Melphalan - UNII:Q41OR9510P) Melphalan. 50 mg in 10 mL. ... Melphalan doses in each arm were: Arm 1: Oral melphalan 0.15 mg/kg/day x 7 followed by 0.05 mg/kg/day when WBC began to rise. ... Arm 2: IV melphalan 16 mg/m2 q 2 weeks x 4 (over 6 weeks) followed by the same dose every 4 weeks. Doses of melphalan were ... Mean (±SD) peak melphalan plasma concentrations in myeloma patients given IV melphalan at doses of 10 or 20 mg/m2 were 1.2 ± ...
a zip file of the full study records in XML for all studies in the search results table (max 10000 ...
Melphalan. Medicine Status PIL SPC XPIL Legal Category Active Ingredient(s) Company Alkeran 2 mg Film-coated Tablets ...
Melphalan injection should only be used to treat people who are unable to take melphalan by mouth. Melphalan is in a class of ... Before receiving melphalan injection, *tell your doctor and pharmacist if you are allergic to melphalan, any other medications ... Melphalan may increase the risk that you will develop other cancers. Talk with your doctor about the risks of taking melphalan. ... Melphalan injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: *nausea ...
Melphalan Flufenamide for Injection for IV Use) may treat, side effects, dosage, drug interactions, warnings, patient labeling ... Melphalan flufenamide is metabolized in tissues to desethyl-melphalan flufenamide and melphalan. Melphalan is metabolized ... melphalan flufenamide despite similar melphalan exposure in animals administered melphalan flufenamide or melphalan. ... elimination half-life of melphalan is 70 minutes (21%). The mean (CV%) clearance of melphalan flufenamide and melphalan is 692 ...
A Study of Melphalan, BCNU, Vitamin B12b, Vitamin C, and Stem Cell Infusion in People With Advanced Pancreatic Cancer and BRCA ... A Study of Melphalan, BCNU, Vitamin B12b, Vitamin C, and Stem Cell Infusion in People With Advanced Pancreatic Cancer and BRCA ... The drug combination is designed to address multiple mechanisms of melphalan resistance. The purpose of the ethanol is the ... melphalan, Vitamin C, BCNU, Ethanol, Autologous Hematopoietic Stem Cells, Vitamin B12B, Vitamin B12B ...
Inquiry for China Melphalan 148-82-3 of Anhui Tianrun Chemical Industry Stock Co., Ltd. , China Melphalan 148-82-3 Suppliers & ...
Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation. ...
Melphalan. Severe Bone Marrow Suppression, Hypersensitivity, and Leukemogenicity. *Melphalan should be administered under the ... Melphalan is leukemogenic in humans.. *Melphalan produces chromosomal aberrations in vitro and in vivo and, therefore, should ... Controlled trials comparing intravenous (IV) to oral melphalan have shown more myelosuppression with the IV formulation. ...
Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell ... Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell ... Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell ...
Isolated limb perfusion, Limb salvage, Melphalan, Stewart-Treves lymphangiosarcoma, Tumor necrosis factor ... Methods: In 10 patients with multifocal Stewart-Treves lymphangiosarcoma of the extremities, 16 ILPs with TNF plus melphalan ... Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangiosarcoma. ... and melphalan is a safe and highly effective procedure that can achieve limb salvage in ≥80% of all patients with nonresectable ...
Rats were perfused with sham (A), 50 μg IL-2 (B), 40 μg melphalan (C), and IL-2 plus melphalan (D), after which tumors were ... Rats were perfused with sham (A), 50 μg IL-2 (B), 40 μg melphalan (C), and IL-2 plus melphalan (D), after which tumors were ... BN175 cells in vitro were treated with medium, 10 μg/mL IL-2, 8 μg/mL melphalan or IL-2 plus melphalan and after 30 minutes of ... Addition of IL-2 to melphalan did not alter the IC50 of melphalan in both cell types. Incubation of HUVEC with IL-2 did not ...
keywords = "Busulfan, Fludarabine, Melphalan, Reduced-intensity conditioning",. author = "Tania Jain and Fares Alahdab and ... Fludarabine with busulfan (FB) or melphalan (FM) are 2 more commonly used reduced-intensity conditioning (RIC) regimens for ... N2 - Fludarabine with busulfan (FB) or melphalan (FM) are 2 more commonly used reduced-intensity conditioning (RIC) regimens ... AB - Fludarabine with busulfan (FB) or melphalan (FM) are 2 more commonly used reduced-intensity conditioning (RIC) regimens ...
Pepaxto (melphalan flufenamide) Melphalan flufenamide is a peptide-conjugated alkylating drug acting by crosslinking of DNA, ... Approval for melphalan flufenamide was based on the phase 2, single-arm HORIZON study (n = 157). The overall response rate (ORR ... Melphalan flufenamide is indicated for using in combination with dexamethasone for relapsed or refractory multiple myeloma in ... and showing synergistic cytotoxicity with dexamethasone in melphalan-resistant and nonresistant multiple myeloma cell lines. ...
Melphalan inhibits mitosis by cross-linking DNA strands; it ultimately disrupts nucleic acid function. ...
Cytarabine/etoposide/lomustine/melphalan Reactions Weekly (2016). * Antineoplastics Reactions Weekly (2016). * Ciclosporin/ ...
... melphalan , melphalan hcl , melphalan hydrochloride , melphalanum , p-bis(beta-chloroethyl)aminophenylalanine , p-di-(2- ... Melphalan is used to treat different cancers including myeloma, melanoma and ovarian cancer. NCATS ... Melphalan is a bifunctional alkylating agent which produces a number of DNA adducts with the DNA interstrand crosslink (ICL) ... Melphalan, also known as L-phenylalanine mustard, phenylalanine mustard, L-PAM, or L-sarcolysin, is a phenylalanine derivative ...
Buy Melphalan Methyl Ester from Daicel Pharma Standards , the leading Pharmaceutical Impurities Manufacturer and Supplier. ...
... approved a new formula of melphalan under the brand name Evomela to treat pati... ... Melphalan at the 2015 BMT Tandem Meeting" Business Wire, "FDA Grants Spectrum Pharmaceuticals Approval of EVOMELA™ (melphalan) ... Evomela (melphalan) approved to treat multiple myeloma. (RxWiki News) The US Food and Drug Administration (FDA) approved a new ... "The improved stability of the CE-Melphalan HCl formulation may potentially ensure that cancer patients receive the full, ...
Chemical Compound MELPHALAN HYDROCHLORIDE , Compound overview, Drug targets, Compound forms, Similar compounds , canSAR.ai ...
Antibody Amp4/42 recognises the ring-opened structure that forms when DNA is alkylated by the anti-cancer drug melphalan and is ... Anti-Melphalan-modified DNA [MP5/73] Invented by Dr Michael Tilby at University of Newcastle upon Tyne The Institute of Cancer ... Anti-Melphalan-modified DNA [Amp4/42] Invented by Dr Michael Tilby from University of Newcastle upon Tyne Invented at ... The Amp4/42 clone did not bind to alkali-treated control DNA or to DNA that had been alkylated with melphalan but not exposed ...
Melphalan Injection / Alphalan Injection, Regoratenib Tablets 40 Mg, Celcarb 450mg Injection and Bleocel Bleomycin 15units ...
LTD is leading manufacturer,exporter and supplier company of Alkacel-2 2 MG Melphalan Tablest IP from Mumbai, Maharashtra, ... 2 MG Melphalan Tablets IP. Minimum Order Quantity : 100. Storage Instructions : Room Temperature. Fermentation Smell : Strong ... Alkacel-2 2 MG Melphalan Tablest IP is used to treat cancer of ovaries and a type of cancer of bone marrow known as myeloma. ... Alkacel-2 2 MG Melphalan Tablets IP is composed in the most controlled environment under the guidance of expert pharmacologists ...
Melphalan, AREA[OverallStatus], Open or Pending Clinical Trials, 147 Results, Page 4 ... Melphalan, AREA[OverallStatus], Open or Pending: 147 Clinical Trials, Page 4 of 15. « First Page «…2 3 4 5 6 …10 15 … »Last ... Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus ...
Dive into the research topics of Autologous stem cell transplantation for Hodgkins disease: Busulfan, melphalan and thiotepa ... Autologous stem cell transplantation for Hodgkins disease: Busulfan, melphalan and thiotepa compared to a radiaton-based ... Autologous stem cell transplantation for Hodgkins disease: Busulfan, melphalan and thiotepa compared to a radiaton-based ... Autologous stem cell transplantation for Hodgkins disease : Busulfan, melphalan and thiotepa compared to a radiaton-based ...
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. ...
  • Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. (themmrf.org)
  • Fludarabine with busulfan (FB) or melphalan (FM) are 2 more commonly used reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (HCT).We present a systematic review and meta-analysis of studies comparing these 2 RIC regimens. (elsevier.com)
  • In total, 92 patients received total body irradiation, cyclophosphamide and etoposide (TBI/CY/ E) (n = 42) or busulfan, melphalan and thiotepa (Bu/Mel/ T) (n = 50) supported with ASCT. (elsevier.com)
  • rior to busulfan and melphalan? (bvsalud.org)
  • Melphalan is used to treat multiple myeloma (a type of cancer of the bone marrow). (medlineplus.gov)
  • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. (semanticscholar.org)
  • RxWiki News) The US Food and Drug Administration (FDA) approved a new formula of melphalan under the brand name Evomela to treat patients with multiple myeloma . (rxwiki.com)
  • The results of the trial, which evaluated melphalan flufenamide in combination with dexamethasone versus pomalidomide (Pomalyst) / dexamethasone in relapsed / refractory multiple myeloma, showed that overall survival (OS) with the experimental design was not improved compared to the control, with a risk ratio of 1 .104 (95% CI, 0.846-1.441). (regiofora.com)
  • High doses of melphalan (HDM) and dexamethasone were administered to 43 patients with advanced multiple myeloma, 36 of whom were refractory to both standard melphalan-prednisone and vincristine-adriamycin- dexamethasone (VAD). (ashpublications.org)
  • Alphalan 2 mg (Melphalan) Tablet is used to treat ovaries' cancer, and a type of bone marrow type called multiple myeloma. (ivermectin24hr.com)
  • Occurence after treatment with melphalan for multiple myeloma. (nih.gov)
  • 2019. High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. . (cornell.edu)
  • Phase I: The primary purpose of this study phase is to determine the best dose also referred to as the maximum tolerated dose (MTD) of Selinexor when used in combination with high-dose melphalan as a conditioning regimen for hematopoietic cell transplant. (survivornet.com)
  • Melphalan hydrochloride for injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. (nih.gov)
  • Melphalan hydrochloride for injection is supplied as a sterile,nonpyrogenic, freeze-dried powder. (nih.gov)
  • Each single-dose vialcontains melphalan hydrochloride equivalent to 50 mgmelphalan and 20 mg povidone. (nih.gov)
  • Melphalan hydrochloride forinjection is reconstituted using the sterile diluent provided. (nih.gov)
  • Melphalan hydrochloride for injection isadministered intravenously. (nih.gov)
  • Melphalan flufenamide hydrochloride is soluble in most organic solvents, while sparsely soluble in aqueous solutions. (rxlist.com)
  • Each vial contains 20 mg melphalan flufenamide (equivalent to 21.48 mg melphalan flufenamide hydrochloride) and 1,000 mg sucrose. (rxlist.com)
  • Melphalan injection should be given only under the supervision of a doctor with experience in the use of chemotherapy medications. (epnet.com)
  • Thus, opioids, antidepressants, the common chemotherapy drug Melphalan - the mussels tested positive for all of them. (wdef.com)
  • Melphalan flufenamide is an alkylating drug. (rxlist.com)
  • Following discussions with the FDA, INN melphalan flufenamide was withdrawn from the market in the United States based on data from the Phase 3 OCEAN study. (regiofora.com)
  • however, Oncopeptides and the FDA intend to continue to work together to ensure that the agent will be available to people currently being treated with melphalan flufenamide. (regiofora.com)
  • In July 2021, the The FDA has partially suspended all clinical trials using melphalan flufenamide following updated OCEAN results. (regiofora.com)
  • Melphalan flufenamide obtained accelerated authorization in February 2021. (regiofora.com)
  • Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation. (pneumotox.com)
  • Eduardo F de P, Bezinelli LM, Lopes RM da G, Nascimento Sobrinho JJ, Hamerschlak N, Corrêa L. Efficacy of cryotherapy associated with laser therapy for decreasing severity of melphalan-induced oral mucositis during hematological stem-cell transplantation: a prospective clinical study. (usp.br)
  • He underwent an HLA-identical sibling peripheral blood stem cell transplantation with fludarabine and melphalan as conditioning chemotherapies before the procedure. (ons.org)
  • Take melphalan at around the same time every day. (medlineplus.gov)
  • Take melphalan exactly as directed. (medlineplus.gov)
  • Your doctor will probably tell you not to take melphalan. (medlineplus.gov)
  • Melphalan injection should only be used to treat people who are unable to take melphalan by mouth. (epnet.com)
  • Methods: In 10 patients with multifocal Stewart-Treves lymphangiosarcoma of the extremities, 16 ILPs with TNF plus melphalan were performed. (eur.nl)
  • No signs of significant vascular damage were detected to account for this observation, although the tumor sections of the IL-2- and IL-2 plus melphalan-treated animals revealed scattered extravasation of erythrocytes compared with the untreated animals. (aacrjournals.org)
  • Your doctor will probably not want you to receive melphalan injection. (epnet.com)
  • OUTLINE: Patients receive melphalan intra-arterially (IA) on day 1. (ucsf.edu)
  • Controlled trials comparing intravenous (IV) to oral melphalan have shown more myelosuppression with the IV formulation. (nih.gov)
  • The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, low-dose I.V. ethanol, vitamin B12b, and vitamin C in association with autologous hematopoietic stem cell infusion. (centerwatch.com)
  • Melphalan injection comes as a powder to be mixed with liquid to be slowly injected intravenously (into a vein) over 15 to 30 minutes by a doctor or nurse in a medical facility. (epnet.com)
  • Giving melphalan via intra-arterial injection may make it less likely that children will need surgery to remove the eye and may reduce the amount of treatment side effects. (ucsf.edu)
  • Mean (±SD) peak melphalan plasma concentrations in myeloma patients given IV melphalan at doses of 10 or 20 mg/m 2 were 1.2 ± 0.4 and 2.8 ± 1.9 mcg/mL, respectively. (nih.gov)
  • Melphalan is used to treat different cancers including myeloma, melanoma and ovarian cancer. (liu.edu)
  • Alkacel-2 2 MG Melphalan Tablest IP is used to treat cancer of ovaries and a type of cancer of bone marrow known as myeloma. (fedeltyhealthcare.in)
  • High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. (semanticscholar.org)
  • The purpose of this pilot study was to evaluate the efficacy of Percutaneous Hepatic Perfusion with high dose Melphalan (PHP-M) as second/last line therapy in patients with advanced or recurrent iCC. (clinicsinsurgery.com)
  • Melphalan is a bifunctional alkylating agent which produces a number of DNA adducts with the DNA interstrand crosslink (ICL) considered to be the critical cytotoxic lesion. (liu.edu)
  • The cytotoxic effects of single extract or extract and melphalan combination were examined by a neutral red assay to investigate their antiproliferative and apoptosis induction effects in the U937 and HepG2 cell lines. (biomedcentral.com)
  • Melphalan is an alkylating agent and a derivative of mechlorethamine that inhibits mitosis by cross-linking DNA strands. (medscape.com)
  • A monofunctional derivative of melphalan: preparation, DNA alkylation products, and determination of the specificity of monoclonal antibodies that recognize melphalan-DNA adducts. (ximbio.com)
  • ILP with either IL-2 or melphalan alone has no antitumor effect, but the combination of IL-2 and melphalan resulted in a strong synergistic tumor response, without any local or systemic toxicity. (aacrjournals.org)
  • In elderly patients or patients in whom autologous transplantation is not possible in the future, melphalan and prednisone (MP) therapy is preferred because of its ease of administration and low toxicity. (medscape.com)
  • has investigated the response and toxicity of intravitreal melphalan treatment for non-vitreous retinoblastoma that was refractory to multiple-course ophthalmic artery chemosurgery (OAC). (rb-net-mdt.org)
  • Combining the P. kesiya extract with melphalan reduced toxicity while retaining the therapeutic efficacy of melphalan. (biomedcentral.com)
  • Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. (semanticscholar.org)
  • Although the contribution of renal elimination to melphalan clearance appears to be low, one study noted an increase in the occurrence of severe leukopenia in patients with elevated BUN after 10 weeks of therapy. (nih.gov)
  • ILP with tumor necrosis factor (TNF) and melphalan is a safe and highly effective procedure that can achieve limb salvage in ≥80% of all patients with nonresectable extremity soft tissue sarcoma or melanoma. (eur.nl)
  • The improved stability of the CE-Melphalan HCl formulation may potentially ensure that cancer patients receive the full, intended therapeutic dose of therapeutic dose of IV melphalan" by increasing the use time and infusion time, said Dr. Parameswaran Hari, professor of hematology at the Medical College of Wisconsin and director of the Adult Blood and Marrow Transplant Program at Froedtert Hospital, in a press release. (rxwiki.com)
  • Patients Three eyes received a median of 7 weekly intravitreal melphalan injections (30μg/0.07cc). (rb-net-mdt.org)
  • tell your doctor and pharmacist if you are allergic to melphalan, any other medications, or any of the ingredients in melphalan tablets. (medlineplus.gov)
  • Alkacel-2 2 MG Melphalan Tablets IP is composed in the most controlled environment under the guidance of expert pharmacologists. (fedeltyhealthcare.in)
  • SECONDARY OBJECTIVES: I. To estimate the ocular salvage rate after treatment with intra-arterial melphalan in children with newly diagnosed unilateral retinoblastoma with group D disease. (ucsf.edu)
  • PRIMARY OBJECTIVES: I. To study the feasibility of delivering melphalan directly into the ophthalmic artery in children with newly diagnosed unilateral group D retinoblastoma, who would otherwise be considered for enucleation. (ucsf.edu)
  • Antibody Amp4/42 recognises the ring-opened structure that forms when DNA is alkylated by the anti-cancer drug melphalan and is then exposed to alkali. (ximbio.com)
  • This study aims to determine the synergistic effects of the chemotherapeutic drug melphalan and the phytoconstituents extracted from Pinus kesiya Royle ex Gordon ( Simaosong ) in human cancer cells. (biomedcentral.com)
  • The synergistic effects of different IC 50 ratios of the P. kesiya extract and melphalan combination were analyzed in each cancer cell line. (biomedcentral.com)
  • The synergistic effect of the whole extract of P. kesiya plus the chemotherapeutic drug melphalan is of interest as it may expand the use of this herbal plant. (biomedcentral.com)
  • This study aims to determine the synergistic effects of P. kesiya and melphalan phytoconstituents ​in human cancer cells. (biomedcentral.com)
  • A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. (semanticscholar.org)
  • IL-2 enhanced significantly melphalan uptake in tumor tissue. (aacrjournals.org)
  • This new formulation also facilitates the use of normal saline instead of propylene glycol (PG), which is in the original formulation of melphalan. (rxwiki.com)
  • Your doctor may need to delay your treatment or adjust your dose of melphalan depending on your response to treatment and any side effects that you experience. (medlineplus.gov)
  • In the current clinical trial, participants with BRCA-related metastatic pancreatic cancer will receive a combination of melphalan, BCNU, low-dose ethanol, vitamin B12b, and vitamin C in conjunction with autologous stem cell infusion. (centerwatch.com)
  • This small case series highlights that non-vitreous disease that is refractory or persistent despite prior OAC can regress with intravitreal melphalan. (rb-net-mdt.org)
  • IL-2 can cause vascular leakage and edema and for this reason we examined the antitumor activity of a combined treatment with IL-2 and melphalan in our well-established ILP in soft tissue sarcoma-bearing rats (BN175). (aacrjournals.org)
  • Melphalan salt is practically insoluble in acetone andchlorinated organic solvents. (nih.gov)
  • Melphalan is also used to treat a certain type of ovarian cancer (cancer that begins in the female reproductive organs where eggs are formed). (medlineplus.gov)
  • Melphalan is also sometimes used to treat breast cancer. (medlineplus.gov)
  • tell your doctor if you have taken melphalan before, but your cancer did not respond to the medication. (medlineplus.gov)
  • Melphalan produces chromosomal aberrations in vitro and in vivo and, therefore, should be considered potentially mutagenic in humans. (nih.gov)
  • Antibody recognition of melphalan adducts characterized using immobilized DNA: enhanced alkylation of G-Rich regions in cells compared to in vitro. (ximbio.com)
  • We hypothesized that plant extracts that exhibited an anticancer activity in vitro might enhance the antiproliferative activity of melphalan, which would permit the use of a lower dosage and reduced side effects. (biomedcentral.com)
  • you should know that melphalan may interfere with the normal menstrual cycle (period) in women and may temporarily or permanently stop sperm production in men. (medlineplus.gov)
  • The drug combination is designed to address multiple mechanisms of melphalan resistance. (centerwatch.com)
  • Mederan-10 - Melphalan is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials. (gnhindia.com)
  • 3. Is high-dosage therapy with melphalan 200mg/m2 supe- fits and harms for the analyzed ages. (bvsalud.org)
  • Melphalan may cause side effects. (medlineplus.gov)
  • Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. (cdc.gov)